
Rehanzil40 mg+1 mg
Incepta Pharmaceuticals Ltd.
Relugolix + Estradiol + Norethindrone is a fixed-dose combination of a GnRH receptor antagonist (relugolix) with low-dose "add-back" hormone therapy (estradiol and norethindrone acetate) and more.
Relugolix + Estradiol + Norethindrone is a fixed-dose combination of a GnRH receptor antagonist (relugolix) with low-dose "add-back" hormone therapy (estradiol and norethindrone acetate), indicated in premenopausal women for:
Relugolix + Estradiol + Norethindrone is not indicated for use in men; it is a women's-health combination product distinct from relugolix monotherapy used for advanced prostate cancer. It is not intended as a contraceptive, and effective non-hormonal contraception should be used if pregnancy is possible.
| Indication | Dose |
|---|---|
| Heavy menstrual bleeding associated with uterine fibroids | One tablet (relugolix 40 mg/estradiol 1 mg/norethindrone acetate 0.5 mg) by mouth once daily |
| Moderate to severe endometriosis-associated pain | One tablet by mouth once daily |
Treatment with Relugolix + Estradiol + Norethindrone should be started within the first 7 days of the onset of menses. If estrogen-containing contraceptives were used previously, Relugolix + Estradiol + Norethindrone should generally be started the day after the last active pill/ring/patch is stopped, per physician guidance.
If a dose of Relugolix + Estradiol + Norethindrone is missed, it should be taken as soon as remembered on the same day, then the regular once-daily schedule resumed the next day. Do not take two doses on the same day to make up for a missed dose.
Not established; Relugolix + Estradiol + Norethindrone is not indicated in pediatric or premenarchal patients.
No dose adjustment has been established for renal impairment. Relugolix + Estradiol + Norethindrone is contraindicated in patients with hepatic impairment or active liver disease (see Contraindications).
Adverse effects of Relugolix + Estradiol + Norethindrone differ somewhat by indication:
Other effects include changes in bone mineral density and lipid parameters (see Precautions and Warnings for details, which are not repeated here).
Relugolix + Estradiol + Norethindrone is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.